Exporting Canadian Cannabis to the UK: What Producers Need Before the First Shipment

For years, Germany was the only serious European destination for Canadian medical cannabis. That is changing. On 22 September 2026, Canopy Growth announced a supply agreement with GROW Group in the United Kingdom to bring four Canadian grown medical flower strains to UK patients, and it pointed to the renewed EU-GMP certification at its Kincardine, Ontario site as the reason it could do so. For Canadian licensed producers, the message is clear. The UK is now a second European market worth preparing for, and the producers who get their quality and licensing files in order first will win the shelf space.

The UK is a very different market from Germany, where recent export data shows Canada is already losing ground without EU-GMP. Medical cannabis in Britain is a controlled drug, most of it is supplied as unlicensed specials, and every shipment passes through both a Health Canada export permit and a UK Home Office import licence before it can move. This guide walks through exactly what a Canadian producer needs, in order, before the first pallet leaves the loading dock.

Executive Summary

Exporting medical cannabis from Canada to the UK requires three coordinated approvals and one underlying quality foundation. Here is the short version.

Two permits per shipment. Health Canada issues a cannabis export permit only to licensed parties, and only after an import permit from the destination country is in hand. The UK Home Office issues a separate import licence for each shipment.
EU-GMP is the gatekeeper. UK importers and wholesalers must confirm a valid GMP certificate for the site of manufacture, and buyers expect EU-GMP certified processing plus GACP compliant cultivation.
Most UK medical cannabis is unlicensed. It is supplied as specials prescribed by specialist doctors, which changes the documentation and release expectations.
Documentation wins deals. Certificates of analysis, batch records, stability data and GACP evidence are what UK buyers audit before they sign.
Plan the timeline. Health Canada targets 30 business days for export permits and the Home Office targets 10 working days for import licences, so build several weeks of lead time into every order.

Why the UK Just Became Canada's Next Cannabis Opportunity

What changed: in September 2026, a major Canadian producer signed its first UK medical cannabis supply deal, confirming that Britain is opening to Canadian grown flower. Why it matters: the UK is one of Europe's largest medical cannabis markets after Germany, and it rewards producers who can prove pharmaceutical grade quality. What to do: treat UK readiness as a licensing and quality project now, not a sales conversation later.

The UK legalised prescribing of cannabis based products for medicinal use in November 2018, when specialist doctors were first allowed to prescribe them. Demand has grown steadily since, served largely by private clinics and unlicensed products imported from a small number of trusted producers. Canadian producers that already invested in an EU-GMP and GACP certification roadmap for Germany are best placed to add the UK, because the quality foundation is the same even though the licences are not.

How the UK Regulates Medical Cannabis

What it is: in the UK, cannabis is a Schedule 2 controlled drug, and most medical cannabis is supplied as an unlicensed special, not as a licensed medicine. Why it matters: unlicensed status changes who can prescribe it, how it is released and what quality evidence the supply chain needs. What to do: understand which route your product takes before you design your documentation.

Licensed medicines versus unlicensed specials

Only a small number of cannabis based medicines hold a UK marketing authorisation. The large majority of products prescribed to patients are unlicensed cannabis based products for medicinal use, known as CBPMs. These are manufactured or imported for individual patients against a prescription and supplied as specials. Because they are unlicensed, they do not carry a marketing authorisation, so the supply chain relies on GMP evidence and batch testing rather than a product licence to assure quality.

Who can prescribe and dispense

An unlicensed CBPM can only be prescribed by a doctor listed on the General Medical Council Specialist Register, not by a general practitioner acting alone. Products are dispensed by registered pharmacies, and the supply chain typically includes special importers and licensed wholesalers. For a Canadian exporter, this means your product will pass through a regulated UK partner before it reaches a patient, and that partner's licences are part of your compliance chain.

The Three Approvals You Need Before You Ship

What it is: every compliant shipment clears a Canadian export permit, a UK import licence and a GMP backed supply chain. Why it matters: missing any one stops the shipment at the border. What to do: run all three workstreams in parallel, because they depend on each other.

Approval	Who issues it	What it covers	Typical timing
Cannabis export permit	Health Canada	Per-shipment authorization for a licensed party to export cannabis for medical or scientific purposes	30 business days (service standard target)
Import licence	UK Home Office	Per-shipment authorization to import a Schedule 2 controlled drug into the UK	10 working days (target); valid 3 months, single use
GMP certificate and specials supply	MHRA	Confirms the site meets GMP and the product can be supplied as a special	Site inspection dependent

1. The Health Canada export permit

Only licensed parties under the Cannabis Regulations may export cannabis, and only for medical or scientific purposes. Before Health Canada will issue an export permit, you must provide an import permit issued by the competent authority in the final destination country. A permit is required for each individual shipment, and each application is assessed case by case. Health Canada also confirms that the shipment will not breach the destination country's laws and that the destination has not reached its annual import limit for cannabis. The department applies a non-binding service standard of 30 business days from payment to decision.

2. The UK Home Office import licence

On the UK side, the importer must hold a domestic controlled drug licence or qualify as an exempt body, and must apply through the Home Office National Drugs Control System. Each shipment needs its own import licence, which is valid for three months, is single use and costs 24 pounds. Valid applications are normally processed in about 10 working days. Licences cannot be backdated, you cannot over-ship or import a different product than listed, and applications for internationally controlled substances are assessed against International Narcotics Control Board estimates. The UK importer, not the Canadian exporter, holds this licence.

3. MHRA GMP and the specials supply chain

The MHRA requires a valid GMP certificate for the site of manufacture, and manufacturers or importers of CBPMs must hold the appropriate manufacturing or wholesale authorisation. For specials, release is performed by a nominated quality controller rather than a Qualified Person in the way a licensed medicine would require, but the supply chain still expects a valid GMP certificate, a certificate of analysis and evidence of good agricultural and collection practice for cultivation. If you already track how the MHRA relies on other regulators, you will recognise the pattern: the UK leans on GMP inspection outcomes and documentation rather than repeating every assessment itself.

Why EU-GMP Certification Is the Real Gatekeeper

What it is: EU-GMP certification of your processing site is the quality credential that unlocks UK and wider European supply. Why it matters: without it, UK importers cannot confirm the GMP status their supply chain checks demand. What to do: secure and maintain EU-GMP certification, backed by GACP compliant cultivation, before you chase UK contracts.

EU-GMP, set out in EudraLex Volume 4, is the standard European buyers and regulators recognise. The UK and Canada also maintain a mutual recognition agreement covering GMP, which supports recognition of Health Canada inspections. That helps, but it does not remove the need for a site GMP certificate. Because most UK medical cannabis is supplied as unlicensed specials rather than licensed medicines, the practical baseline the UK supply chain expects is a valid GMP certificate, in practice EU-GMP, for the manufacturing or processing site, plus batch level certificates of analysis. In short, the mutual recognition agreement supports how your GMP status is accepted, but the EU-GMP certificate is still what you need to hold.

If you are not yet certified, start with how and why Canadian producers get EU-GMP certified. Avoid the shortcut of GMP washing, where product is finished offshore to claim a credential the Canadian site has not earned, because it puts every downstream buyer at risk. And if you are weighing your options, understand the difference between EU-GMP and GPP so you certify to the standard the destination market actually requires.

Requirement	Germany	United Kingdom
Product status	Prescription medicine, mostly unlicensed and pharmacy dispensed	Mostly unlicensed special, prescribed by specialist doctors
Quality baseline	EU-GMP certified product and GACP cultivation	Valid GMP certificate for the site (EU-GMP in practice) and GACP cultivation
Import control	Import authorization under German medicines and narcotics law	Home Office import licence per shipment
Who imports	German pharmaceutical importer or wholesaler	UK licensed importer, wholesaler or special importer

The Documentation UK Buyers Will Audit

What it is: the quality dossier a UK importer reviews before accepting your product. Why it matters: UK buyers and the MHRA supply chain checklist expect specific documents, and gaps stall or kill deals. What to do: assemble a UK ready dossier before your first buyer audit. Expect requests for the following.

A valid GMP certificate for the site of manufacture.
A batch specific certificate of analysis that matches the destination specification.
GACP evidence for the cultivation of each lot.
Finished product specifications.
Stability data that justifies the labelled shelf life and expiry.
Labelling that meets UK requirements for unlicensed CBPMs.
Batch manufacturing and packaging records.
A written quality or technical agreement with the UK partner.

In our experience, the gaps that cost producers a UK contract are predictable. Certificates of analysis that do not match the buyer's specification, stability data that does not support the claimed shelf life, GACP records that are incomplete for a specific harvest, and quality agreements that leave release responsibilities unclear. Treat each gap as a formal corrective and preventive action with a documented root cause, not a one off fix, because UK buyers and their auditors look for a functioning quality system, not patched paperwork. Export markets can also turn quickly, as Canadian producers saw when Israel opened an anti-dumping questionnaire on Canadian cannabis, so a clean, defensible file protects you when scrutiny rises.

Compliance Checklist: UK Export Readiness

Use this checklist to gauge whether your organization is ready to pursue a UK medical cannabis contract.

Confirm your facility holds current EU-GMP certification and GACP compliant cultivation records.
Identify a UK importer or wholesaler that holds the required Home Office and MHRA licences.
Obtain the UK import permit before applying for your Health Canada export permit.
Apply for a per-shipment Health Canada cannabis export permit and allow 30 business days or more.
Confirm a UK Home Office import licence is in place for each shipment (valid 3 months, single use).
Prepare a batch specific certificate of analysis matching the UK specification.
Assemble stability data that supports the labelled shelf life.
Compile GACP cultivation evidence for each harvest lot.
Put a written quality and technical agreement in place with your UK partner.
Confirm labelling meets UK requirements for unlicensed CBPMs.
Verify the destination has not reached its annual cannabis import limit.
Keep complete export records for audit and inspection.

Common Mistakes Canadian Exporters Make

Treating the UK like Germany. Different licences, different documentation and different prescribing rules apply.
Planning volumes before securing a UK partner. The import licence sits with a licensed UK importer, so no partner means no permit.
Assuming the mutual recognition agreement clears everything. It supports GMP recognition, but unlicensed specials still need a valid site GMP certificate and batch documentation.
Underestimating permit timelines. Over-promising a delivery date is a fast way to lose a new buyer's trust.
Weak GACP records. Cultivation evidence is scrutinised as closely as processing.
Mismatched certificates of analysis. A CoA that does not map to the buyer's specification triggers questions you do not want at the border.

Frequently Asked Questions

Can Canadian companies legally export cannabis to the UK?

Yes. Licensed parties under the Cannabis Regulations may export cannabis for medical or scientific purposes, provided they hold a Health Canada export permit and the UK importer holds the required Home Office import licence for the shipment.

Do I need EU-GMP to sell medical cannabis in the UK?

In practice, yes. UK importers and wholesalers must confirm a valid GMP certificate for the site of manufacture, and EU-GMP is the standard the European supply chain recognises. GACP compliant cultivation is expected alongside it.

Is medical cannabis a controlled drug in the UK?

Yes. Cannabis is a Schedule 2 controlled drug in the UK, so importing it requires a Home Office import licence for each shipment, and prescribing an unlicensed product is restricted to specialist doctors.

How long does a Health Canada cannabis export permit take?

Health Canada's non-binding service standard is 30 business days from payment, although performance has historically fallen short of that target, so plan for longer and never assume best case timing.

Who holds the UK import licence, the Canadian exporter or the UK buyer?

The UK importer holds the Home Office import licence. Health Canada will not issue your export permit until the UK import permit exists, so you need a licensed UK partner in place first.

Does the UK-Canada mutual recognition agreement remove the need for a GMP certificate?

No. The agreement supports recognition of GMP inspections, but because most UK medical cannabis is supplied as unlicensed specials, the supply chain still requires a valid GMP certificate for the manufacturing site and batch specific documentation.

How MFLRC Can Help

MFLRC helps Canadian producers build UK and European export readiness end to end. Our regulatory and quality consulting team supports EU-GMP and GACP certification, Quality Assurance Person (QAP) services, export dossier and documentation preparation, GMP gap assessments, SOP development, and Compliance-as-a-Service retainers for producers scaling into new markets. If the UK is on your roadmap, we can pressure test your quality file before a buyer or regulator does.

Book an Export-Readiness Gap Assessment

Conclusion

The UK is opening, but it rewards preparation over speed. Producers with EU-GMP certification, complete GACP cultivation records, a licensed UK partner and a clean quality dossier will move first, while those who treat the UK like a copy of Germany will stall at the paperwork. Start the licensing and quality work now, and let the sales conversations follow a file that is already ready to ship.